However, they also found in another study that this marker is stable in other diseases, while TRIM59 and KLF14 showed hypermethylation in early-onset Alzheimer’s disease, and hypermethylation of TRIM59 and hypomethylation of FHL2 in Graves’ disease (Spólnicka et al. 2018b). Here, TRIM59 is linked to Graves disease.